Selected research
Industry Research
Neisseria meningitidis Infections Drug Industry Research Report 2026
Market perspective
The global Neisseria meningitidis Infections Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Neisseria meningitidis Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Neisseria meningitidis Infections Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Neisseria meningitidis Infections Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Neisseria meningitidis Infections Drug include Biological E Ltd, Griffith University, ImmunoBiology Ltd, JN-International Medical Corp, MGB Biopharma Ltd, Panacea Biotec Ltd, Sanofi Pasteur SA, Serum Institute of India Ltd and Wellstat Vaccines LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Neisseria meningitidis Infections Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neisseria meningitidis Infections Drug Market by Company
Biological E Ltd
Griffith University
ImmunoBiology Ltd
JN-International Medical Corp
MGB Biopharma Ltd
Panacea Biotec Ltd
Sanofi Pasteur SA
Serum Institute of India Ltd
Wellstat Vaccines LLC
Beijing Minhai Biotechnology Co Ltd
GlaxoSmithKline Plc
China National Pharmaceutical Group Corp
Pfizer Inc
Neisseria meningitidis Infections Drug Segment by Type
TP-10
NCL-195
MGBBP-3
Others
Neisseria meningitidis Infections Drug Segment by Application
Hospital
Clinic
Others
Neisseria meningitidis Infections Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neisseria meningitidis Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neisseria meningitidis Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neisseria meningitidis Infections Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neisseria meningitidis Infections Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neisseria meningitidis Infections Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neisseria meningitidis Infections Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- TP-10
- NCL-195
- MGBBP-3
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Biological E Ltd
- Griffith University
- ImmunoBiology Ltd
- JN-International Medical Corp
- MGB Biopharma Ltd
- Panacea Biotec Ltd
- Sanofi Pasteur SA
- Serum Institute of India Ltd
- Wellstat Vaccines LLC
- Beijing Minhai Biotechnology Co Ltd
- GlaxoSmithKline Plc
- China National Pharmaceutical Group Corp
- Pfizer Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neisseria meningitidis Infections Drug Market Size (2021-2032)
- 2.2.2 Global Neisseria meningitidis Infections Drug Sales (2021-2032)
- 2.2.3 Global Neisseria meningitidis Infections Drug Market Average Price (2021-2032)
- 2.3 Neisseria meningitidis Infections Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 TP-10
- 2.3.3 NCL-195
- 2.3.4 MGBBP-3
- 2.3.5 Others
- 2.4 Neisseria meningitidis Infections Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neisseria meningitidis Infections Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Neisseria meningitidis Infections Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Neisseria meningitidis Infections Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Neisseria meningitidis Infections Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Neisseria meningitidis Infections Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Neisseria meningitidis Infections Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neisseria meningitidis Infections Drug, Product Type & Application
- 3.8 Global Manufacturers of Neisseria meningitidis Infections Drug, Established Date
- 3.9 Global Neisseria meningitidis Infections Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biological E Ltd
- 4.1.1 Biological E Ltd Company Information
- 4.1.2 Biological E Ltd Business Overview
- 4.1.3 Biological E Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 4.1.5 Biological E Ltd Recent Developments
- 4.2 Griffith University
- 4.2.1 Griffith University Company Information
- 4.2.2 Griffith University Business Overview
- 4.2.3 Griffith University Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Griffith University Neisseria meningitidis Infections Drug Product Portfolio
- 4.2.5 Griffith University Recent Developments
- 4.3 ImmunoBiology Ltd
- 4.3.1 ImmunoBiology Ltd Company Information
- 4.3.2 ImmunoBiology Ltd Business Overview
- 4.3.3 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 4.3.5 ImmunoBiology Ltd Recent Developments
- 4.4 JN-International Medical Corp
- 4.4.1 JN-International Medical Corp Company Information
- 4.4.2 JN-International Medical Corp Business Overview
- 4.4.3 JN-International Medical Corp Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolio
- 4.4.5 JN-International Medical Corp Recent Developments
- 4.5 MGB Biopharma Ltd
- 4.5.1 MGB Biopharma Ltd Company Information
- 4.5.2 MGB Biopharma Ltd Business Overview
- 4.5.3 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 4.5.5 MGB Biopharma Ltd Recent Developments
- 4.6 Panacea Biotec Ltd
- 4.6.1 Panacea Biotec Ltd Company Information
- 4.6.2 Panacea Biotec Ltd Business Overview
- 4.6.3 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 4.6.5 Panacea Biotec Ltd Recent Developments
- 4.7 Sanofi Pasteur SA
- 4.7.1 Sanofi Pasteur SA Company Information
- 4.7.2 Sanofi Pasteur SA Business Overview
- 4.7.3 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolio
- 4.7.5 Sanofi Pasteur SA Recent Developments
- 4.8 Serum Institute of India Ltd
- 4.8.1 Serum Institute of India Ltd Company Information
- 4.8.2 Serum Institute of India Ltd Business Overview
- 4.8.3 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 4.8.5 Serum Institute of India Ltd Recent Developments
- 4.9 Wellstat Vaccines LLC
- 4.9.1 Wellstat Vaccines LLC Company Information
- 4.9.2 Wellstat Vaccines LLC Business Overview
- 4.9.3 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolio
- 4.9.5 Wellstat Vaccines LLC Recent Developments
- 4.10 Beijing Minhai Biotechnology Co Ltd
- 4.10.1 Beijing Minhai Biotechnology Co Ltd Company Information
- 4.10.2 Beijing Minhai Biotechnology Co Ltd Business Overview
- 4.10.3 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolio
- 4.10.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
- 4.11 GlaxoSmithKline Plc
- 4.11.1 GlaxoSmithKline Plc Company Information
- 4.11.2 GlaxoSmithKline Plc Business Overview
- 4.11.3 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolio
- 4.11.5 GlaxoSmithKline Plc Recent Developments
- 4.12 China National Pharmaceutical Group Corp
- 4.12.1 China National Pharmaceutical Group Corp Company Information
- 4.12.2 China National Pharmaceutical Group Corp Business Overview
- 4.12.3 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolio
- 4.12.5 China National Pharmaceutical Group Corp Recent Developments
- 4.13 Pfizer Inc
- 4.13.1 Pfizer Inc Company Information
- 4.13.2 Pfizer Inc Business Overview
- 4.13.3 Pfizer Inc Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolio
- 4.13.5 Pfizer Inc Recent Developments
5 Global Neisseria meningitidis Infections Drug Market Scenario by Region
- 5.1 Global Neisseria meningitidis Infections Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Neisseria meningitidis Infections Drug Sales by Region: 2021-2032
- 5.2.1 Global Neisseria meningitidis Infections Drug Sales by Region: 2021-2026
- 5.2.2 Global Neisseria meningitidis Infections Drug Sales by Region: 2027-2032
- 5.3 Global Neisseria meningitidis Infections Drug Revenue by Region: 2021-2032
- 5.3.1 Global Neisseria meningitidis Infections Drug Revenue by Region: 2021-2026
- 5.3.2 Global Neisseria meningitidis Infections Drug Revenue by Region: 2027-2032
- 5.4 North America Neisseria meningitidis Infections Drug Market Facts & Figures by Country
- 5.4.1 North America Neisseria meningitidis Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Neisseria meningitidis Infections Drug Sales by Country (2021-2032)
- 5.4.3 North America Neisseria meningitidis Infections Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Neisseria meningitidis Infections Drug Market Facts & Figures by Country
- 5.5.1 Europe Neisseria meningitidis Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Neisseria meningitidis Infections Drug Sales by Country (2021-2032)
- 5.5.3 Europe Neisseria meningitidis Infections Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Neisseria meningitidis Infections Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neisseria meningitidis Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Neisseria meningitidis Infections Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Neisseria meningitidis Infections Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neisseria meningitidis Infections Drug Market Facts & Figures by Country
- 5.7.1 South America Neisseria meningitidis Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Neisseria meningitidis Infections Drug Sales by Country (2021-2032)
- 5.7.3 South America Neisseria meningitidis Infections Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Neisseria meningitidis Infections Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neisseria meningitidis Infections Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Neisseria meningitidis Infections Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Neisseria meningitidis Infections Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Neisseria meningitidis Infections Drug Sales by Type (2021-2032)
- 6.1.1 Global Neisseria meningitidis Infections Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Neisseria meningitidis Infections Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Neisseria meningitidis Infections Drug Revenue by Type (2021-2032)
- 6.2.1 Global Neisseria meningitidis Infections Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Neisseria meningitidis Infections Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Neisseria meningitidis Infections Drug Sales by Application (2021-2032)
- 7.1.1 Global Neisseria meningitidis Infections Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Neisseria meningitidis Infections Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Neisseria meningitidis Infections Drug Revenue by Application (2021-2032)
- 7.2.1 Global Neisseria meningitidis Infections Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Neisseria meningitidis Infections Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neisseria meningitidis Infections Drug Value Chain Analysis
- 8.1.1 Neisseria meningitidis Infections Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neisseria meningitidis Infections Drug Production Mode & Process
- 8.2 Neisseria meningitidis Infections Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neisseria meningitidis Infections Drug Distributors
- 8.2.3 Neisseria meningitidis Infections Drug Customers
9 Global Neisseria meningitidis Infections Drug Analyzing Market Dynamics
- 9.1 Neisseria meningitidis Infections Drug Industry Trends
- 9.2 Neisseria meningitidis Infections Drug Industry Drivers
- 9.3 Neisseria meningitidis Infections Drug Industry Opportunities and Challenges
- 9.4 Neisseria meningitidis Infections Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst